Displaying 13 - 24 of 27
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Displaying 13 - 24 of 27